Press coverage about Nuvectra Corporation (NASDAQ:NVTR) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nuvectra Corporation earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.199078881663 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Nuvectra Corporation (NVTR) opened at $8.46 on Tuesday. Nuvectra Corporation has a 12-month low of $4.63 and a 12-month high of $15.00. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.72 and a current ratio of 2.90.

Nuvectra Corporation (NASDAQ:NVTR) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.07. The company had revenue of $7.60 million during the quarter, compared to the consensus estimate of $8.08 million. Nuvectra Corporation had a negative net margin of 204.19% and a negative return on equity of 68.63%. The company’s quarterly revenue was up 100.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.92) EPS. equities analysts forecast that Nuvectra Corporation will post -4.77 EPS for the current fiscal year.

A number of research analysts recently weighed in on NVTR shares. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $12.00 target price on shares of Nuvectra Corporation in a research report on Friday, November 3rd. ValuEngine downgraded shares of Nuvectra Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $12.00.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Nuvectra Corporation (NVTR) Stock Price” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at

Nuvectra Corporation Company Profile

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Insider Buying and Selling by Quarter for Nuvectra Corporation (NASDAQ:NVTR)

Receive News & Stock Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related stocks with our FREE daily email newsletter.